BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $272,234 | $249,666 | $265,652 | $174,678 |
| - Cash | $408,741 | $31,518 | $963 | $1,698 |
| + Debt | $2,887 | $2,834 | $0 | $0 |
| Enterprise Value | -$133,620 | $220,982 | $264,689 | $172,980 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$49,000 | -$29,912 | -$23,083 | -$21,827 |
| % Margin | – | – | – | – |
| Net Income | -$44,757 | -$28,435 | -$22,055 | -$19,687 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.9 | 0.039 | -0.02 | 0.12 |
| % Growth | -4,959.3% | 295.5% | -116.7% | – |
| Operating Cash Flow | -$70,626 | -$23,293 | -$735 | -$88 |
| Capital Expenditures | -$533 | -$231 | $0 | $0 |
| Free Cash Flow | -$71,159 | -$23,524 | -$735 | -$88 |